216 related articles for article (PubMed ID: 21557634)
21. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.
Chiang CL; Kandalaft LE; Coukos G
Int Rev Immunol; 2011; 30(2-3):150-82. PubMed ID: 21557641
[TBL] [Abstract][Full Text] [Related]
22. Tumor vaccine for ovarian carcinoma targeting sperm protein 17.
Chiriva-Internati M; Wang Z; Salati E; Timmins P; Lim SH
Cancer; 2002 May; 94(9):2447-53. PubMed ID: 12015770
[TBL] [Abstract][Full Text] [Related]
23. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
Neeson P; Paterson Y
Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer biology and immunotherapy.
Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
[TBL] [Abstract][Full Text] [Related]
25. Vaccine-based clinical trials in ovarian cancer.
Leffers N; Daemen T; Boezen HM; Melief KJ; Nijman HW
Expert Rev Vaccines; 2011 Jun; 10(6):775-84. PubMed ID: 21692699
[TBL] [Abstract][Full Text] [Related]
26. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
27. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.
Wefers C; Lambert LJ; Torensma R; Hato SV
Gynecol Oncol; 2015 May; 137(2):335-42. PubMed ID: 25727651
[TBL] [Abstract][Full Text] [Related]
28. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cells for specific cancer immunotherapy.
Meidenbauer N; Andreesen R; Mackensen A
Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
[TBL] [Abstract][Full Text] [Related]
30. Tumour immunotherapy: the adjuvant treatment of the 21st century?
Bremers AJ; Kuppen PJ; Parmiani G
Eur J Surg Oncol; 2000 Jun; 26(4):418-24. PubMed ID: 10873365
[TBL] [Abstract][Full Text] [Related]
31. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.
Adams M; Navabi H; Croston D; Coleman S; Tabi Z; Clayton A; Jasani B; Mason MD
Vaccine; 2005 Mar; 23(17-18):2374-8. PubMed ID: 15755631
[TBL] [Abstract][Full Text] [Related]
32. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma.
Wei S; Kryczek I; Edwards RP; Zou L; Szeliga W; Banerjee M; Cost M; Cheng P; Chang A; Redman B; Herberman RB; Zou W
Cancer Res; 2007 Aug; 67(15):7487-94. PubMed ID: 17671219
[TBL] [Abstract][Full Text] [Related]
34. Current developments in cancer vaccines and cellular immunotherapy.
Ribas A; Butterfield LH; Glaspy JA; Economou JS
J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
[TBL] [Abstract][Full Text] [Related]
35. Emerging immunotherapies in ovarian cancer.
Ojalvo LS; Nichols PE; Jelovac D; Emens LA
Discov Med; 2015 Sep; 20(109):97-109. PubMed ID: 26463091
[TBL] [Abstract][Full Text] [Related]
36. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cell immunotherapy in ovarian cancer.
Stiff PJ; Czerlanis C; Drakes ML
Expert Rev Anticancer Ther; 2013 Jan; 13(1):43-53. PubMed ID: 23259426
[TBL] [Abstract][Full Text] [Related]
38. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
39. Cancer vaccine development: on the way to break immune tolerance to malignant cells.
Mocellin S; Rossi CR; Nitti D
Exp Cell Res; 2004 Oct; 299(2):267-78. PubMed ID: 15350526
[TBL] [Abstract][Full Text] [Related]
40. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
Wagner U; Köhler S; Reinartz S; Giffels P; Huober J; Renke K; Schlebusch H; Biersack HJ; Möbus V; Kreienberg R; Bauknecht T; Krebs D; Wallwiener D
Clin Cancer Res; 2001 May; 7(5):1154-62. PubMed ID: 11350879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]